New strip drug targets debilitating itch in rare liver disease
NCT ID NCT06733519
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2a trial tests TH104, a nalmefene strip placed inside the cheek, for moderate to severe itching in primary biliary cholangitis (PBC). About 40 adults with PBC will receive either TH104 or a placebo to see if it safely reduces itch. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nalmefene (given as a dissolvable strip placed inside the cheek)
- What this could lead to
- If it works, this could point toward a new treatment option for severe itching in people with primary biliary cholangitis.
- What could go wrong
- This is an early Phase 2a study with only 40 people, focused mainly on safety. It may not show enough benefit to move forward, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a different opioid reduce Post-C-Section itching?
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Can a pill stop the relentless itch of a liver disease? a major trial aims to find out.
- Scientists launch study to unravel mysterious chronic itch
- Dialysis itch relief: could a simple education program be the answer?